<DOC>
	<DOC>NCT03095040</DOC>
	<brief_summary>This randomized, double blind, phase 2/3 study is aimed to evaluate the efficacy and safety of CM082 in combination with everolimus in Chinese patients with advanced renal cell carcinoma. The primary endpoint is progression-free survival.</brief_summary>
	<brief_title>CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically or cytologically confirmed diagnosis of clear cell renal cell carcinoma Progressed on at least one standard therapy with VEGFR TKI Measurable disease per Recist v1.1 Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1 Life expectancy of at least 12 weeks Adequate organ functions, and meet the following requirements: Bone marrow: ANC ≥1.5*109/L (1500/mm3), platelet ≥100*109/L, and hemoglobin ≥9 g/dL Liver: Total bilirubin ≤1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5x the upper limit of normal (ULN) if no liver involvement or ≤5x the upper limit of normal with liver involvement Kidney: Creatinine ≤ 1.25 x ULN, urine protein &lt;1+ Heart: LVEF ≥ 50% Willingness and ability to comply with trial and followup procedures Ability to understand the nature of this trial and give written informed consent Currently receiving anticancer treatment; currently or previously have received 2 or more systemic anticancer treatment Other tumors in addition to renal cell carcinoma Females who are pregnant or breastfeeding Known hypersensitivities to CM082 or everolimus Those with concurrent condition(e.g. psychological, neuronal, cardiovascular, respiratory conditions or infections) that in the investigator's opinion would jeopardize compliance with the protocol Patients with known central nervous system (CNS) metastases Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of CM082 or everolimus Any active infection Drug or alcohol abuser</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>